First participant dosed in Phase 1 clinical trial of EQ504, proof-of-mechanism data expected in Q2 2027 Cash equivalents of $53.3 million as of September 30, 2026; pro forma cash balance of approximately $72.0 million after the net effect of $20 million in gross financing received in October 2026 Cash runway expected into 2029 LA JOLLA, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology innovator developing novel therapies to treat serious autoimmune and i ...